Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896207 · ClinicalTrials.gov registry record · Phase 1
Studying Different Formulations of SR13668 in Healthy Volunteers
A Phase 1 study of Healthy, no Evidence of Disease, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00896207 is a Phase 1 study of Healthy, no Evidence of Disease that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants, below the 175-participant average among 11 other Healthy, no Evidence of Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00896207, a Phase 1 study of Healthy, no Evidence of Disease, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized early phase I trial is studying different formulations of SR13668 in healthy volunteers. Giving SR13668 may help doctors learn more about how SR13668 is used by the body. It is not yet known which formulation of SR13668 is most effectively used by the body.
Conditions Studied
Interventions
- DRUG Akt inhibitor SR13668
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896207
The ClinicalTrials.gov registry entry for NCT00896207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 11 other Healthy, no Evidence of Disease trials with a reported enrollment target (89% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy, no Evidence of Disease appearing as the primary indexed condition, and to 1 intervention - of which Akt inhibitor SR13668 is the first listed.
NCT00896207 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00896207 about?
NCT00896207 is a clinical study titled "Studying Different Formulations of SR13668 in Healthy Volunteers". This randomized early phase I trial is studying different formulations of SR13668 in healthy volunteers. Giving SR13668 may help doctors learn more about how SR13668 is used by the body. It is not yet known which formulation of SR13668 is most effectively used by the body.
What is the current status of trial NCT00896207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-06. Estimated completion is 2010-03.
What conditions does trial NCT00896207 study?
This clinical trial studies the following conditions: Healthy, no Evidence of Disease.
What interventions are being tested in trial NCT00896207?
The interventions under investigation include: Akt inhibitor SR13668 (DRUG).
Who is sponsoring clinical trial NCT00896207?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00896207 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy, no Evidence of Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diindolylmethane in Healthy Volunteers
COMPLETED · Phase 1
-
Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
COMPLETED · Phase 1
-
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients
COMPLETED · Phase 1
-
Lycopene in Healthy Male Participants
COMPLETED · Phase 1
-
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
COMPLETED · Phase 1
-
A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.